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ABSTRACT
Understanding how conformational dynamics play a role in metabolic regulation is an
important objective in various biological disciplines. Using Molecular Dynamics (MD)
simulations, we attempt to elucidate the dynamics involved in regulating two glycolytic
enzymes: human liver pyruvate kinase (hL-PYK) and human enolase. Despite being
metabolically coupled, both enzymes are regulated quite differently: hL-PYK can undergo
allosteric modulation, while enolase is competitively inhibited. In the hL-PYK study, we discern
a mechanism of allostery induced by the allosteric activator fructose-1,6-bisphosphate, and the
inhibitor alanine. In the case of enolase, previous studies have attempted to make isoformspecific inhibitors of the enzyme; to further explore this objective, we compare the dynamics of
two conserved isozymes, enolase 1 and 2, through MD simulations. As a proof of concept, we
find compounds that discriminate between the two homologues by performing ensemble virtual
screening on MD derived free enolase structures.
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1
1.1

INTRODUCTION

The Role of Conformational Dynamics in Protein Regulation
Cellular metabolism is the fundamental set of chemical reactions that distinguish living

organisms from their counterparts. In order to maintain cellular homeostasis, the metabolic
enzymes governing metabolism must have regulatory features that shift their catalytic function
upon signal.1 These regulatory mechanisms may vary: some enzymes undergo allosteric
modulation, some are regulated directly from the active site, and others are regulated through
post-translational modification.2-4 What these processes all have in common are that they induce
regulation by perturbing protein dynamics, and because these enzymes can sample a range of
structural conformations, it is essential to understand their dynamics. 5 This study will focus on
the dynamics of two metabolically coupled enzymes that have distinct regulatory features:
enolase which undergoes inhibition through competitive binding in the active site and the
allosteric enzyme human liver pyruvate kinase (hL-PYK).
The interest in understanding the dynamics of metabolic enzymes stems from its
relevance to drug discovery and lead-optimization studies. A range of complex diseases that stem
from metabolic pathways are still present due to the lack of effective therapeutics. One way to
mitigate this issue is to explore structure-function relationships in drug targets (typically
enzymes), and to then find compounds that regulate the enzyme through analysis of receptorligand interactions.6-8 Over the years, rational structure-based drug discovery studies have proven
beneficial in the clinical realm, with the most notable example being the now approved drug
Dorzolamide, an inhibitor to carbonic anhydrase.9 In fact, a significant number of approved
drugs have been found through investigation of x-ray crystal structures of proteins. 10 Yet, as
insightful as x-ray crystallographic and NMR data are, these methods are not without their
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limitations. Aside from the relatively expensive costs in running these experiments, these
techniques ultimately generate static models, and oftentimes neglect the structural dynamics of
the protein-ligand complexes as a result.11 Though cases may exist where molecules bind into a
static pocket of an enzyme as detailed by the lock-and-key model, the consensus is that ligands
instead bind to an ensemble of receptor conformations, and that upon binding, the ligand induces
conformational changes that shift the dynamics to sample a different population. 12 For this
reason, incorporating computational tools like molecular dynamics, which inexpensively
predicts the intricate motions in macromolecular systems are in demand in drug discovery
efforts.13

1.2

Purpose of this Study
Our aim in the first part of this study is to elucidate the differences in dynamics between

two Enolase homologues: human enolase 1 and 2. Different tissues have varying expressions of
enolase isozymes, all of which perform the same function, while specific tumor cells have only
expressions of one enolase homologue.14 As a result, attempts have been made in finding
competitive inhibitors that are selective to one homologue.15-16 The challenge is that these
isozymes are highly conserved (>80% sequence similarity).17 For this reason, we suggest that the
structural dynamical differences between these homologues could aid in determining ligand
selectivity. In this study, we compare the dynamics of enolase 1 and 2 using MD simulations. In
addition, we run MD simulations of enolase 1 and 2 bound to HEX, an inhibitor specific to
enolase 2. Finally, we run ensemble virtual screening on both homologues in an attempt to find
compounds that could distinguish between the two highly conserved isozymes.
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Aside from competitively inhibiting enzymes, there is a growing desirability in
developing drugs that exhibit selectivity to allosteric sites of proteins. 18 Allosteric regulation is
defined as the transference of dynamical information from a remote region of an enzyme to its
catalytic site, thereby altering both the structure and function of the molecular body. 19
Traditionally, allosteric perturbations arise when a ligand or effector molecule binds to a target
macromolecule; studies have extended the definition to include perturbations of distal residues. 20
Pyruvate kinase is often regarded as a textbook allosteric protein, for it houses multiple allosteric
sites, each responsible for different effector molecules; and though the enzyme’s allosteric
regulation process is well characterized, the structural details remain elusive. 21 For the second
part of this study, we focus on the enzyme human liver pyruvate kinase (hL-PYK). Our aim is to
gain insight on the dynamics induced by two allosteric effectors: the activator fructose-1,6bisphoshate (FBP) and the inhibitor alanine, by comparing MD simulations of hL-PYK in the
presence and absence of these allosteric effectors.

1.3

Regulation of Glycolysis
Glycolysis is an ancient well characterized metabolic pathway that involves the

breakdown of glucose to form pyruvate and ATP. 22 The significance of glycolysis is that many
of its intermediates are essential to different aspects of cellular function, including the pentose
phosphate pathway, citric acid cycle, etc.23 The ten enzymes involved in glycolysis are
complicated as well. For one, there can be multiple tissue-specific isozymes representing just one
reaction step; these proteins can even be found performing functions outside of catalysis. 24
Because the net production of ATP from glycolysis is extremely low, normal functioning cells
will shuttle pyruvate through oxidative phosphorylation. 23 When oxygen levels are low however,
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the pyruvate formed from glycolysis is instead reduced to lactate (anaerobic glycolysis). 25
Muscle cells also undergo anaerobic glycolysis, and the lactate generated is normally shuttled out
(Cori cycle) where it is converted into glucose by the liver; otherwise, abnormal accumulation of
lactate can lead to a variety of issues.26 Interestingly, tumor cells upregulate anaerobic glycolysis
regardless of oxygen levels, leading to the production of lactate. 27-29 This phenomenon, dubbed
the Warburg effect, is the reason that a variety of cancer therapeutic studies target glycolysis.
The two glycolytic enzymes in this study are metabolically coupled. Enolase catalyzes
the dehydration of 2-phosphoglycerate (2-PG) to phosphoenolpyruvate, which is then converted
to pyruvate by pyruvate kinase.22 Apart from their metabolic proximity, both enzymes share a
share a considerable homology.30 In fact, comparison studies on yeast enolase and pyruvate
kinase propose that the two enzymes evolved from a common ancestral protein. 30 The
comparisons between both enzymes end here however, since they can be regulated differently. In
this study, we individually explore the structural dynamics involved in regulating both enzymes.

Figure 1.1 Glycolysis with an emphasis on its last two reactions.
(A) The glycolysis pathway. (B) The last two reactions of glycolysis.
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2
2.1

Computational Chemistry

Molecular Dynamics
Enzymes and nucleic acids have dynamical characteristics that are oftentimes physically

undetectable using conventional experiments.31 The field of Computational Chemistry presents a
solution to this barrier by accounting for the microscopic state ensemble using molecular
dynamics, which allows one to study and analyze the structural features of a macromolecular
system.32 Over the years, MD has been used in a variety of investigations including protein
folding, simulations of biomolecules, ligand binding studies, etc. 33-35
Conceptually, two branches of molecular dynamics exist – quantum mechanical (QM)
and classical MD. QM molecular dynamics is seen as more precise because it considers the
contributions of valence shell electrons in the electrostatic interactions, while attributing classical
integration with the nucleus and inner electrons. 36 Though this technique is more explicit, it’s a
computationally expensive tool as it requires a great deal of time and resources. This is
especially the case when dealing with large-scale macromolecules. In contrast, the classical
approach creates a coarse-grained model by ignoring the outer valence shell electron
contributions, making the technique less computationally expensive. 37
Classical MD is a statistical mechanics method that centers on Newton’s Second Law of
Motion, one of the foundational principles of classical mechanics. 38 For every MD simulation, an
initial set of coordinates are required. These coordinates can come from x-ray crystallography,
NMR solution, and even cryo-EM data. Considering the scope and size of the two enzymes in
this study, we will use classical MD simulations to discern the dynamics, using x-ray
crystallographic data as our starting coordinates.
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2.1.1

Classical Molecular Dynamics

Classical molecular dynamics is based on Newton’s Second Law of Motion, where the
force (Fi) of a single atom is equal to the mass of the atom (mi) times the acceleration of that
atom (ai). The acceleration is the derivative of velocity (v), and velocity is the derivative of
displacement (ri).39

𝐹 = 𝑚𝑎 = 𝑚

( )

= 𝑚

(1)

The purpose of MD is to calculate the motions of a molecular system; but to find these
motions, the forces acting upon each atom needs to be calculated. 40 Since the force is equal to the
negative gradient of a scalar potential energy function (equation 2), one can take the potential
energy of all interacting atoms U(r1,…,rN) as a function of their positions.40 Then, the gradient
(∇) of that function with respect to the displacement of the atoms can be taken. Finally, the force
acting on every atom can be calculated.

𝐹 = −∇ 𝑈(𝑟 , … , 𝑟 ) = −

,

,

(2)

The potential of each individual atom is governed by a set of bonded and nonbonded
potential terms: the bond valence, length, and dihedral angle potentials, as well as the nonbonded
van der Waals and electrostatic potentials.39 The first potential in equation 3 describes the
harmonic vibrational motions between atom pairs that are covalently bonded, where li is the bond
length and li0 is the equilibrium potential. The next potential, the angular potential, describes the
angular vibrational motion that occurs between bonded atoms, where bi is the harmonic force
constant, where 𝜃 is the bond angle, and 𝜃 is the equilibrium potential. The third potential in
equation 3, the torsion angle potential, describes the dihedral motions, where four consecutively
linked atoms (two sets of three atoms, with two in common) are accounted for; the ci term
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represents heights of rotational barriers, and n denotes periodicity. The next two potential terms
describe nonbonded potentials between atom pairs 𝑖 and 𝑗. The van der Waals potential, which
accounts for interatomic forces between unpaired atoms, is modeled by the Lennard-Jones 6-12
potential. In this term, r is the distance between the two atoms, 𝜎 is the distance where the
intermolecular potential between the atom pairs is zero, and ε is the well depth. Lastly, the
electrostatic potential, modelled by Coulomb’s Law, describes the attractive and repulsive forces
that occur from charged atoms. In this term, the charges are denoted by q i and qj, while the
distance between the two atoms is denoted by rij.

𝑈(𝑟 , … , 𝑟 ) = ∑
cos(𝑛𝑤 − 𝛾 )) + ∑

(𝑙 − 𝑙 ) + ∑

,

4𝜀

(𝜃 − 𝜃 ) + ∑
−

+ ∑

,

𝑘

(1 +
(3)

Upon calculations of the potential terms, the force vectors of each atom can be evaluated
and used to compute their motions. The Verlet integration algorithm (equation 4) is used to
calculate the trajectories of the individual atoms by their position and velocity vectors, with
respect to time.41

𝑟 (𝑡 + ∆𝑡) ≅ 2𝑟 (𝑡) − 𝑟 (𝑡 − ∆𝑡) +

( )

∆𝑡

(4)

The Verlet algorithm relies on initial atomic coordinates and a proper choice of a
timestep. Conventionally, the initial atomic coordinates are taken from x-ray crystallographic or
NMR data. As for the choice of a timestep, a femtosecond timestep is considered ideal; one must
be aware that choosing a timestep too small can lead to unnecessarily small atomic motions,
while drastically increasing it could give rise to inaccurate motions. 42
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2.1.2

Current State and Outlook of MD

Molecular dynamics studies have proven useful in unearthing a multitude of biologically
relevant phenomena. One successful example of MD applied to drug discovery involved a study
of Eph tyrosine kinases, where a snapshot representative of the overall conformation of the
simulation trajectories were taken and used as a receptor for high-throughput screening. 43 This
was proven useful, given that the x-ray crystallographic structures of the enzymes did not sample
the conformations necessary for adequate docking. MD studies have also successfully led to the
finding of allosteric sites, otherwise undetectable experimentally. 44 Despite the number of
successes, there are two challenges in the field of MD that should be addressed: the atomic force
fields used in simulations need further improvements, and technical limitations hinder us from
procedurally running simulations at more robust timescales. 45
Regarding the first limitation, the force fields used in molecular dynamics simulations are
only approximations of quantum mechanical effects. 39 Considering that classical MD has proven
reliability in predicting correct molecular motions for macromolecules, this is not always a
hinderance; however, the disregard for QM effects can still be a detriment to studies that involve
transition metals and ligand binding events.46 In classical MD, atoms are assigned fixed partial
charges; but in reality, electron clouds move, and so the charge of each atom fluctuates based on
the surrounding dynamical environment. Of course, this limitation can be marginally mitigated
by implementing QM calculations, but such computations are rigorous and expensive. There is a
compromise: computational studies can incorporate hybrid techniques, where QM calculations
are incorporated in a select area of a macromolecule, such as the active site of an enzyme or
charge calculations of a coordinating transition metal, while the rest of the molecular body is
governed by classical mechanics.48
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Another significant challenge in MD, one that is more pressing, is the issue of sampling.
Across the biological world, it is known that a variety of macromolecules can explore multiple
conformational ensembles over long periods of time.49 Unfortunately, MD simulations are
currently limited to microsecond timescales (with notable exceptions), and some important
dynamical motions can even take form after hours. 50 There are proposed solutions to sampling,
however. One such solution is accelerated molecular dynamics (aMD), which involves the
reduction of large energy barriers, enabling proteins to sample conformational states that would
otherwise be inaccessible from conventional simulations. 51 Though artifacts could arise from this
method, it is nonetheless a feasible solution. Other solutions include replica exchange molecular
dynamics (REMD) and high temperature simulations, both of which have proven to be
effective.52
The biggest driving force towards the progress in MD is of course the hardware. As
computational power expands, the ability to simulate larger systems over longer periods of time
increases. Where MD simulations were once calculated on CPUs, todays software packages like
the updated AMBER suite are designed to run MD calculations on GPUs, enhancing the speed of
MD computations exponentially in comparison. Also, Nvidia manages to release new GPUs
relatively quickly and this leads to significant increases in computational power. For example,
the hL-PYK simulations in this study comprises of over 200,000 atoms, and the simulation ran
for ~16 nanoseconds per day on a NVIDIA GTX 980. When the same system ran on an upgraded
GTX 1080, the simulation speed increased to approximately 25 ns/day. Ultimately, the progress
in computational power allows for increase in simulation timescales, and one can soon look to
running routine microsecond-long simulations.
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2.2

Methods of Analyzing MD Simulations
2.2.1

Root Mean Square Deviation

In Computational Chemistry, the root mean square deviation (RMSD) method measures
the average distances between atoms of molecules superimposed onto one another. 53 Specific to
MD simulations, the RMSD calculations are generally performed on the backbone atoms of a set
of snapshots acquired from a trajectory; these snapshots are superimposed onto the reference
structure, which is usually the starting coordinates of the simulation. When it applies to these
studies, RMSD calculations are useful in determining whether a simulation is equilibrated, which
is when a structure samples a stable average conformation. Equation 4 defines RMSD, where N
denotes the number of snapshots/frames of a trajectory, and denotes the distance between atom
and its reference coordinates:

𝑅𝑀𝑆𝐷 =

2.2.2

∑

𝑟

(5)

Root Mean Square Fluctuation

The root mean square fluctuations (RMSF) is the measure of displacement of a set of
atoms with respect to the reference structure, averaged over the number of atoms involved. 54
Like the RMSD method, RMSF calculations rely on alignment of backbone atoms onto a
reference structure. Unlike RMSD however, RMSF calculations can be useful for analyzing an
equilibrated trajectory (where the reference structure is an equilibrated snapshot), because it
provides insights on the fluctuations of residues of an enzyme with respect to a sample of stable
snapshots.
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2.2.3

Principal Component Analysis

Principal component analysis (PCA) is a statistical technique that reduces the number of
dimensions of a dataset to describe the most important elements of that dataset. 55 While the
datasets used in PCA may have linearly correlated variables, the technique extracts the
information into a set of linearly uncorrelated variables referred to as principal components (PC).
In the context of molecular dynamics simulations, PCA is useful when applied to the cartesian
coordinates of a given simulation. When applying the technique to the coordinates of the
backbone atoms in a MD trajectory, the most dominant motions of the molecular system can be
captured, and generally those motions are considered the most essential. 56 PCA can also be
applied to all heavy atoms of a set of essential residues, such as binding site residues.

2.2.4

Difference Contact Statistics & Network Analysis

To capture dynamical information at the atomic level, one can observe inter-residue
contact formations and breakages of a molecular system. Sometimes referred to as contact
statistics, the technique considers all heavy atoms of each residue, and measures the distances
between both residues.57 If the distance between the two residues is less than 4.5 Å, then the two
residues are in contact; if none of the atoms are within the cutoff, then there is no contact. Once
the contact probabilities are mapped for each simulation independently, one can measure the
residue-residue contact differences between two simulations. The technique in turn can provide a
network of residue contact differences between the compared simulations. 58 The method has
been used successfully to detail allosteric mechanisms in proteins, perturbations caused by
substrate recognition, etc.59-61 In this study, contact statistics is applied to both enzymatic
systems to capture the perturbations caused by ligand recognition.
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2.3

Molecular Docking
Molecular docking is an essential computational tool in predicting intermolecular

interactions between two molecules.62 Conventional docking studies involve searching a
designated three-dimensional space within a receptor (target molecule), predicting the binding
modes of a ligand through stochastic search methods, and using a proper scoring function to
calculate the binding affinities (∆G) of the ligand poses. 63 The results can garner a list of ligand
poses ranked in accordance to the most favorable protein-ligand interactions. The input data is
arguably the most important aspect. Factors such as receptor conformation(s), search space, and
source of small-molecule structures must all be considered prior to performing docking. Though
this technique has proven effective in a variety of structure-based studies, results from docking
will often trade-off reliability for time efficiency.64 For this reason, docking is recommended
solely for early stage lead-optimization, where the goal is not to find a potential drug, but to
instead use docking results as a rationale for further drug design endeavors. The low
computational cost comes incredibly handy however, since the technique can be scaled up to
screen/dock thousands (even millions) of compounds.
In this study, the software package Autodock Vina65 is used to virtually screen fourhundred thousand drug-like molecules against the enolase 1 and 2 homologues. For the purpose
of this study, a drug-like molecule is defined as any chemical species that fits the Lipinski’s Rule
of Five.66 The structures of the molecules were acquired from the ZINC Database 67, while the
receptor coordinates were obtained from equilibrated MD simulations of free enolase 1 and 2.
Because the interactions between molecules are dynamic in nature, it’s not always ideal to dock
ligands onto a single static structure (as the lock and key model entails), but to instead dock
ligands onto an ensemble of structures, a method referred to as ensemble docking. 68
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3
3.1

The Dynamics of Enolase 1 & 2 Regulation

Introduction
Enolase is a metalloenzyme that catalyzes the conversion of 2-phosphoglycerate to form

phosphoenolpyruvate, the penultimate metabolite in glycolysis. 69 Categorized in the lyase class
of enzymes, enolase catalyzes both the reverse hydrolysis (gluconeogenesis) and forward
dehydration (glycolysis) reactions, making it crucial for metabolic function. In vertebrates, three
glycolytic enolase isoforms (α, β, and γ) exist, and though each homologue is encoded by a
different gene, they are all highly conserved.70 Evolutionary studies suggest that these
homologues are a result of a gene duplication event traced over 300 million years ago. 71 Though
these genes have varying expressions depending on the tissue cells, they all perform the same
function, making enolase a functionally redundant enzyme in cells that express multiple
isoforms; this genetic redundancy is exploitable.
Certain tumor cells like Glioblastoma and Hepatocellular Carcinoma have deletions of
the 1p36 tumor suppressor locus, which contains the ENO1 gene, meaning that these cells
function without α-enolase (enolase 1).14 These tumor cells can still perform glycolytic function
through redundant action of γ-enolase (enolase 2). In contrast, many functioning cells express
both the ENO1 and ENO2 genes and can use both for glycolysis. Studies show that by
selectively inhibiting Enolase 2, the ENO1-deleted tumor cells would lose glycolytic function,
while the remaining cells can rely on enolase 1 for metabolism. 15 This phenomenon of targeting
cells based on gene deficiency is known as collateral lethality. The challenge that comes in
targeting enolase 2, however, is that the homologues share a conserved active site; in fact, the
enzymes share an 83% sequence identity. It is therefore proposed that comparing the dynamics
of enolase 1 and 2 can aide in discerning the structural motions that explain ligand specificity.
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Figure 3.1 Concept of collateral lethality in the context of enolase 1 & 2.
(A) Normal functioning cells can use both isozymes for glycolytic function while specific tumor
cells will have ENO1 gene deletion. (B) Compounds that inhibit enolase 2. (Top)
Phosphonoacetohydroxamate (PhAH). (Middle) SF2312. (Bottom) HEX.
Recently, a natural phosphono-hydroxamate, SF2312, was found to exhibit selective
toxicity towards glioblastoma cells with ENO1 gene deletion. 15 The compound was found to
bind more selectively to enolase 2 than its homologue. The molecule was further developed into
a prodrug (POMSF), which was then tested in vivo.16 Unfortunately, the inhibitor induced
hemolytic anemia in mouse models because of on-target activity against enolase 1 in red-blood
cells. In fact, red blood cells have only enolase 1 expression, and so it was determined that the
compound was not selective enough towards enolase 2. In response to this problem, a new leadcompound was developed, called POMHEX, which is shown to not produce hemolytic anemia.
The HEX-enolase 2 complex was co-crystallized, and the structure has been published in the
Protein Data Bank.
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The first goal in this study is to discern the differences in dynamics between enolase 1
and 2 through MD simulations in apo-state; in addition, we run MD simulations of the two
isozymes complexed with HEX, an inhibitor selective to enolase 2. The second, and perhaps
more ambitious goal of this study, is to perform ensemble virtual screening on both homologues.
It is important to stress that, like any theoretical technique, molecular docking has its limitations.
Where most docking studies attempt to find “hit” molecules with high binding affinities (∆G) to
a target receptor, we attempt to instead compare predicted interactions between a set of ligands
and receptors (free enolase 1 and 2). By performing molecular docking of approximately
400,000 small-molecules, one can take the differences in binding affinities (∆∆G) between both
isozymes and compare the resultant protein-ligand interactions.
3.1.1

Structural Analysis of Enolase 1 & 2

Figure 3.2 Structure of enolase 2 (PDB ID: 4ZCW).
Chain A is color coded: N-terminus domain is cyan, catalytic C-domain is pink, and the loops
L1, L2, and L3 are highlighted in yellow. The active site is in green space-fill.
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Enolase is a homodimer comprised of two domains: An N-terminus “lid” domain, and a
catalytic C-terminus domain comprised of a TIM-barrel fold (eight α-helices and eight βstrands). The enzyme relies on two divalent magnesium cations for function. 72 Upon binding of
the first magnesium cation, enolase undergoes a conformation change that “opens” up the active
site, allowing for substrate binding.73 Once a ligand enters the catalytic site and the binding is
recognized, a flexible loop L1 (residues 36-43) from the N-terminus domain encapsulates the
active site; in addition, two more loops from the TIM-barrel domain, L2 (residues 153-169) and
L3 (residues 251-277), also form a “closed conformation” by partially encasing the active site. 74
For the activity of the enzyme to proceed, both the ligand and a set of carboxy residues in the
active site must loosely coordinate with a second magnesium cation. 75 Crystallographic studies
have shown that competitive inhibitors of enolase can elicit the same L1 loop enclosure that
occurs upon substrate binding, but at varying levels.76

Figure 3.3 Alignment of enolase 1 and 2.
(A) Sequence alignment of enolase 1 and 2 using ClustalW2. (B) Structural superposition of
enolase 2 (PDB 4ZCW)15 and enolase 1 (PDB 2PSN). The residues marked in red are nonconserved, while the residues in cyan are conserved.
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Alignment of enolase 1 and 2 reveals that both proteins are highly conserved. Apart from
their 83% sequence identity, both isozymes retain the same secondary structural elements.
Usually, mechanisms for ligand specificity can be explained by differences in the active site
residues; but the catalytic site for both homologues are conserved, which suggests that a set of
distal residues could be responsible for the differences between the two isoforms. Based on this
observation, it is proposed that by comparing the dynamics of enolase 1 and 2, one can
rationalize the atomic-level motions that are responsible for the differences between the two
homologues – differences that could be exploited for drug discovery studies.

3.2

Experimental Procedures
3.2.1

Preparation of Enolase 1 & 2 for MD

Four systems were generated for this study: enolase 1 and 2 in apo form, and enolase 1
and 2 bound to the HEX inhibitor. The x-ray crystal structure PDB 5TD9 16 was used for the apo
enolase 2 model, while PDB 3B9774 was used for the apo enolase 1 model. The histidine
protonation states were determined by the web-based tool PROPKA (PDB2PQR web server). 77
For consistency, conserved histidine residues between both isoforms were kept with the same
protonation states. To generate the bound enolase models, the ligand coordinates were obtained
from PDB 5IDZ16, an x-ray crystal structure of enolase 2 bound to HEX. The PyMOL 78 software
was used to structurally superimpose this structure to enolase 1 (PDB 3B97), where the
coordinates of HEX were then transferred onto the active sites of the enolase 1 monomers. The
resultant PDB structures were ported onto xLeap to verify fidelity of the clipping. The GAFF2
force field was used to model the HEX ligand.79 MD simulations of enolase 1 and 2 both bound
to HEX were performed based on these initial coordinates.
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3.2.2

MD Simulation of Enolase 1 & 2

The MD simulations were carried out using the CUDA version of the Amber16 suite of
programs79 along with the modified version of the Cornell et al. ff14SB 80 force field, while the
GAFF279 force field was used to parameterize the HEX ligand. The simulations were performed
on the NVIDIA GeForce GTX 980 GPU. Each system was solvated in a TIP3P 81 periodic
octahedron box containing water molecules. Counterions were added to the system to obtain
electrostatic neutrality. All simulations were kept at a temperature of 300 K and a constant
pressure of 1 bar. Electrostatic interactions were calculated using the particle mesh Ewald (PME)
summation method, where long-range nonbonded interactions were accounted for with a 9 Å
cutoff.82 For each system a 2 fs time step was used to solve the equation of motion. After a series
of minimizations, the system was equilibrated with a harmonic constraint through five
subsequent MD simulations of 1 ns each, where the force constant was reduced from 500 to 5
kcal·Å2/mole. A final equilibration step ran for 1 ns, where no harmonic constraints were
conducted, allowing for the enzyme to move freely. A total of 4.4 µs of simulation data was
produced, and the last microsecond from each trajectory was used for analysis. Aside from
PyMOL, images were also generated using the VMD83 software package.

Table 3.1 Summary of MD simulations performed on enolase.
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3.2.3

Virtual Screening of Enolase

Virtual screening was performed with the Autodock Vina65 software. Using the ZINC
Database67, approximately 400,000 compounds following Lipinski’s Rule of Five criteria 66 were
obtained for virtual screening. The files were already in “pdbqt” format, meaning the Gasteiger
charges were already accounted for in each ligand. The method for obtaining proper coordinates
of the receptors was a bit more extensive. As mentioned previously, ligand binding events are
ultimately dynamic in nature, so an ensemble of receptor structures were obtained for the virtual
screening.
To distill the dominant configurations from the MD simulations of apo enolase, PCA was
performed on heavy atoms of the active sites of enolase 1 and 2. PC1 and PC2 were plotted, and
the probability density distributions were calculated. Four representative snapshots, one at the
center of each cluster, was chosen for docking. In total, the four most dominant snapshots from
apo enolase 1 and 2 were used as receptors for virtual screening against 400,000 compounds,
meaning over 2.8 million docking runs were simulated. AutoGrid version 4.0 was used to
generate a periodic box of 13x13x13 Å (1.000 Å spacing) to encapsulate the catalytic site. A
binding affinity/score (∆G) was obtained for each conformation. The virtual screening was
performed on a Linux Beowulf cluster of ~270 cores. Two-dimensional docking pose images
were generated using PoseView.84
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3.3

Results & Discussion
3.3.1

The Dynamics of Free Enolase 1 & 2

Figure 3.4 RMSD of the backbone atoms of free enolase 1 & 2.
(A) RMSD of free enolase 1 simulation. Chain A is in black, and chain B is in red. (B) RMSD of
free enolase 2. Chain A is in black, and chain B is in red.
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Figure 3.5 RMSF of the backbone atoms of free enolase 1 & 2.
(A) RMSF of free enolase 1 (black) and enolase 2 (red). (B) Difference in RMSF of free enolase
1 and 2 (taken by subtracting the RMSF of enolase 1 to enolase 2).
The RMSD of the MD simulations of enolase 1 and 2 reveals that the structures reach
stabilization after the first 100 nanoseconds. Aside from the inferred convergence, it appears that
the trajectory of enolase 1 deviates from its starting coordinates more-so than enolase 2.
Interestingly, the RMSF of both trajectories show that despite the high sequence and structural
homology between both isozymes, their dynamics differ greatly. Enolase 2 appears to fluctuate
more than its counterpart. The oscillations of loops L1 and L2, which are highly conserved,
differ greatly in enolase 1 and 2. The L3 dynamics fluctuate in both simulations as well. The set
of carboxy residues responsible for binding of the second magnesium ion also differ in their
fluctuations.
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Figure 3.6 Residue−residue dCNA of free enolase 1 and 2.
Difference contact network is calculated by comparing the free/apo enolase 1 to free enolase 2.
Blue bars indicate more contact formations from the apo to a substrate-bound network, while red
bars indicate more contact breakages. The non-conserved residues are in orange orbs.
Difference residue-residue contact statistics reveal that the two enolase homologues have
considerable differences in their dynamics, despite being structurally conserved. A close
inspection of the contact network shows that L2 can undergo a great deal of conformational
changes. Three residues in this loop are non-conserved: residues 273, 274, and 265. In the
enolase 1 trajectory, L2 interacts closely with the enzymatic body. In contrast, L2 is expanded
away in the enolase 2 trajectory, resulting in contact breakages. At the active site, the carboxy
residues known to coordinate with the second magnesium cation (absent in free enolase) display
differences in their contact network as well. This could suggest that prior to ligand binding,
enolase 1 and 2 differ in their dynamics, and that these differences in dynamics could influence
ligand selectivity.
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3.3.2

Dynamics Induced by HEX, an Enolase 2 Specific Inhibitor

Figure 3.7 RMSD of the backbone atoms of HEX-enolase complex.
(A) RMSD of HEX-bound enolase 1. (B) RMSD of HEX-bound enolase 2. Chain A is in black,
and chain B is in red.

Figure 3.8 RMSF of the backbone atoms of HEX-enolase complex.
(A) RMSF of both HEX-enolase 1 (black) and HEX-enolase 2 (red). (B) Difference in RMSF
between enolase 1 and 2.
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RMSD reveals that the hex-bound enolase simulations stabilize after 100 nanoseconds.
Like the apo variants, enolase 1 deviates from its starting coordinates more-so than enolase 2.
Interestingly, the HEX-enolase 1 complex appears to display greater dynamic fluctuations
relative to enolase 2. As shown earlier, free enolase 2 fluctuates more so than free enolase 1, but
upon binding of HEX, enolase 1 appears to oscillate more than its homologue. This could
suggest that the ligand stabilizes enolase 2 to fit a more localized conformation.

Figure 3.9 PCA of HEX-bound active site.
(A) Plot of PC1 and PC2 with calculated probability density distributions. Enolase 1 is in black,
and enolase 2 is in red. (B) Active site of HEX-enolase 1 sampled from the center of the cluster,
with the binding pocket at the bottom (surf mode). (C) Active site of HEX-enolase 2 sampled in
the center of the cluster, with the binding pocket shown at the bottom (surf mode).
PCA of the catalytic site reveals notable differences between how enolase 1 and 2
recognize HEX binding. The side-chain dynamics of the residues interacting with HEX appear to
adopt the same conformation, indicating that HEX induces similar dynamical effects on the
interacting residues of both homologues. However, the residues in close proximity to HEX (the

25

ones not directly in contact) sample different motions. PC1 reveals that the key difference is in
the interaction between residues S373 and E210. In HEX-enolase 2, a hydrogen bond interaction
is formed in the active site. In the case of HEX-enolase 1, the hydrogen bond isn’t formed; also,
the L1 loop is slightly sampled away from the ligand. Overall, holo-enolase 1 appears to have a
larger catalytic pocket, suggesting that HEX does not exhibit the same effects on the enzyme
compared to enolase 2.

Figure 3.10 PCA of the backbone atoms of the enolase simulations.
(A) Plot of PC1 and PC2 of the four simulations. (B) PC 1 projected onto the backbone atoms of
the enolase dimer with respective color scales. (C) PC 2 projected onto the backbone atoms of
the enolase dimer with respective color scales.
Principal Component Analysis (PCA) of the backbone atomic coordinates of the enolase
simulations reveal that each protein samples distinct conformations. Here, the free and HEXbound enolase simulations appear to have no overlap, indicating that they sample significant
differences in conformation space. This is a stark contrast to free and boud enolase 1, where
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there is considerable overlap in PC1 and PC2. This could suggest that HEX elicits the greatest
conformational changes to enolase 2, while enolase 1 recognition to HEX is more limited in
comparison. PCA also reveals that despite the large degree of homology, the dominant backbone
motions differ significantly.
Projection of the principals eignevectors can display the representative backbone motions
of the MD simulations. Loops L1 and L3 appear to sample the greatest motions; correlating with
previous crystallographic studies, it appears that these loops sample a more “open” conformation
in the free enolase simulations, while HEX binding is accompanied by a “closed” conformation
in both homologues. The backbone dynamics of L2 are more subtle; in the free enolase 1 and 2
trajectories, L2 fluctuates between an open and closed conformation. In the HEX-bound
simulations, this loop slightly projects more outward (away from the catalytic site).
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Figure 3.11 Dynamic contact statistics of HEX-enolase 1 and 2.
A) Residue−residue difference contact networks are calculated by comparing the free enolase 1
to the bound enolase 1. (B) Residue-residue difference contact networks comparing free enolase
2 to bound enolase 2. Blue bars indicate more contact formations from the apo to a substratebound network, and red bars indicate more contact breakages.
The difference contact statistics of both enolase homologues show that HEX induces
greater dynamical changes to enolase 2. The HEX-bound enolase 2 system appears to sample a
more “closed” conformation, where L1 and L3 move closer to the active site, forming a large
degree of contacts with the rest of the enzyme as a result. In contrast, L2 in bound enolase 1 has
L2 form less contacts with the enzyme as opposed to free enolase 1. The L1 loop does appear to
enclose the active site upon HEX binding, but the degree to which these changes are broadcasted
is much smaller in comparison to the enolase 2 system.
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3.3.3

Ensemble Virtual Screening of Enolase 1 & 2

Figure 3.12 Ensemble selection scheme of enolase 2.
(A) PC1 vs PC2 of the active site residues of enolase 2 reveal distinct clusters. (B) The four
representative structures acquired from the center of each cluster, superimposed.

Figure 3.13 Ensemble selection scheme of enolase 1.
(A) PC1 vs PC2 of the active site residues of enolase 1 reveals distinct cluster. (B) The four
representative structures acquired from the center of each cluster, superimposed.
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To see if the dynamics of the conserved active site of enolase 1 and 2 could influence
ligand specificity, ensemble based virtual screening was performed on the apo trajectories of
enolase 1 and 2. PCA was calculated on the active site residues of enolase 1 and 2. PC1 and PC2
were plotted, and one representative snapshot from each cluster was acquired and docked against
~400,000 compounds. A total of eight receptor structures were used (four from enolase 1 and
four from enolase 2). Based on the representative snapshots acquired from PCA, loop L2 appears
to have a significant degree of structural variability. In some of the receptor snapshots, this loop
is orientated closer to the active site; and in some of the other structures, this loop is shifted
further away (outside of the periodic box). It is apparent then, that prior to binding, the active site
of enolase could potentially sample a range of conformations that would influence ligand
binding.
Table 3.2 Control group scores from virtual screening.
Compound
2-PG

Enolase 1 Scores (kcal/mol)
1
2
3
4
Average
-5.3 -5.6 -5.9 -5.4 -5.5 ± 0.2

Enolase 2 Scores (kcal/mol)
1
2
3
4
Average
-4.9 -5.8 -5.6 -5.2 -5.4 ± 0.3

PEP

-5

-4.5

-5

-5.3

-5.0 ± 0.2

-4.7

-5.5

-5.3

-4.9

-5.1 ± 0.3

Phah

-5.5

-5.7

-4.9

-5.5

-5.4 ± 0.3

-5.1

-5.5

-5.7

-5.2

-5.4 ± 0.2

HEX

-6.2

-5.3

-5.6

-6

-5.8 ± 0.3

-5.8

-5.6

-5.8

-5.7

-5.7 ± 0.1

A set of known enolase ligands were docked onto the ensemble structures as control
trials. As expected, the predicted binding poses all scored favorably to the receptors. In this
study, the binding score of substrate 2-PG is used as the cutoff for finding potential inhibitors. In
other words, any compound that would score more favorably than 2-PG would be considered as
a potential inhibitor for further analysis.
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Table 3.3 Top scoring compounds for enolase 1.
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Figure 3.14 Predicted pose of ZINC000013118752 and its interactions to enolase 1.
(A) ZINC000013118752 docked onto the active site of enolase 1. (B) Predicted interactions
generated by PoseView.
Three of the top five scoring compounds that dock favorably to enolase 1 comprise of
Sulfonamides, a functional group found in a variety of drugs - particularly anti-bacterial and antidiabetic medications.85 In the lowest energy poses of these particular compounds, hydrogen
bonds form between the sulfate group, and K343 and/or R372. These same compounds also pose
favorable binding to Enolase 2; but with less favorable affinity scores (higher ∆G). Another
common feature shared by these compounds are that they comprise of amide bonds, benzenes,
and/or azaarenes. The enolase 1 structures appear to sample a large space in the binding
pocket/cavity, suggesting that the aromatic functional groups can serve as scaffolds that occupy
the space.
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Table 3.4 Top scoring compounds to enolase 2.
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Figure 3.15 Predicted pose of ZINC000005955022 and its interactions with enolase 2.
(A) ZINC000005955022 docked onto the active site of enolase 2. (B) Predicted interactions
generated by PoseView.
Once again, the top scoring hits for enolase have aromatic functional groups, including
benzenes and azaarenes. Interestingly, these compounds appear to have either one or no rotatable
bonds; in contrast, the top scoring enolase 1 hits have more rotatable bonds, meaning that those
compounds have more degrees of freedom. In addition, the top scoring compound to enolase 2
happen to score just as favorably when docked to enolase 1, but the same can’t be said vice
versa.
In an attempt to find potential inhibitors more selective to one isozyme, multiple
rudimentary comparison methods were employed. One method involved averaging the four
binding scores the ligands sampled against the receptors. The differences in binding affinities
(∆∆G) between the ligand pose to enolase 1 versus enolase 2 was then measured. Another
method involved acquiring the top docking pose score of the four trials, and to then measure the
∆∆G between the two homologues’ top hits. It is important to note that Autodock Vina has an
inherent error of approximately -2.8 kcal/mol, which was accounted for when comparing the
differences between the poses and the receptors.
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Table 3.5 Curated list of compounds that bind selectively to enolase 1.

Over a dozen compounds were found to (1) pose more favorably to the enolase 1
receptors than the control group ligands, and (2) score poorly when docked to the enolase 2. Out
of the dozen or so hits, a list of three compounds were curated in table 3.4. Given that selectively
targeting enolase 2 over enolase 1 is a goal in collateral lethality studies, these results came
partly as a surprise. There could be multiple explanations as to why not a single compound
docked significantly more selectively to enolase 2 than its counterpart. For one, this could
suggest that free enolase 1 is more promiscuous. When comparing the MD derived structures, it
appears that free enolase 1 has more space in its catalytic pocket.

Figure 3.16 Docking pose results of ZINC000013135683.
(A) The compound docked onto the active site of enolase 1 (ensemble 4, binding affinity score is
-5.8 kcal/mole). (B) The compound docked onto the active site of enolase 2 (ensemble 1, binding
affinity score of 8.9 kcal/mole).
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3.4

Conclusions
MD simulations of enolase 1 and 2 reveal that though both enzymes are highly conserved

(they share an 83% sequence identity and 94% sequence similarity), their free-state dynamics
differ greatly. This could suggest that the conformation of enolase 1 and 2 prior to ligand binding
could dictate ligand specificity. As a point of interest, we wanted to explore how an enolase 2
selective inhibitor, called HEX, would influence the dynamics of both homologues. Our findings
show that enolase 2 exhibits a great deal of structural changes upon HEX binding, while the
enolase 1 response to HEX is less perceived.
MD simulations can provide representative conformations of proteins that can be absent
in static crystal structures. For this reason, we set out on an ambitious objective: to screen over
400,000 compounds against MD derived Enolase 1 and 2 structures. In some cases, compounds
docked to different representative snapshots more favorably than others. This reaffirms that
enolase 1 and 2 are highly dynamic in free state, with L3 particularly influencing the docking
pose results. Second, a large number of compounds were capable of binding to enolase 1 more
favorably than enolase 2, but not vice versa. This could suggest that enolase 1 is the more
promiscuous homologue, where it samples conformations that allow it to access ligands that are
otherwise inaccessible to enolase 2. Ultimately, our findings show that docking ligands onto a
single static crystal structure alone may not be sufficient, and that if virtual screening were to be
used in lead-compound development, then the receptor dynamics should be taken into account.
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4
4.1

The Dynamics in Allosteric Regulation of hL-PYK

Introduction
Pyruvate kinase (PYK) is an enzyme that irreversibly catalyzes the final step of

glycolysis by transferring phosphate from phosphoenolpyruvate (PEP) to ADP, producing ATP
and pyruvate, both of which are essential for cellular function. 86 Typically, the kinase family of
proteins are categorized as enzymes that phosphorylate their substrates, but pyruvate kinase is
unique because it instead dephosphorylates its own substrate. In mammals, there are four tissuespecific isozymes of pyruvate kinase: M1 (muscle), M2 (fetal), L-Type (liver), and R-Type
(erythrocyte) PYK.87 Due to alternate starting sites, a single gene, PKLR, encodes for both the L
and R pyruvate kinases, while a PKM gene encodes for both the M1 and M2 isozymes. The liver
isozyme in humans, hL-PYK, has an extensive allosteric regulation scheme that is still not fully
understood on a structural level.88
During periods of fasting, glucose is produced in the liver through the process of
gluconeogenesis; to prevent futile breakdown of this newly generated sugar, glycolysis is
downregulated through one of its irreversible steps.89 The enzyme hL-PYK has several extensive
regulatory processes responsible for maintaining this glycolytic/gluconeogenic homeostasis,
making it a relevant target in metabolic regulation studies. 90 Through a process of feed-forward
stimulation, hL-PYK can be allosterically activated by fructose-1,6-bisphosphate, an earlier
glycolytic intermediate. The enzyme can be allosterically inhibited by both alanine and ATP as
well. Unfortunately, studies on the structure of hL-PYK are limited, and so the allosteric
mechanisms involved in the enzyme are ambiguous; that is of course a point of interest. By
running MD simulations of hL-PYK both in the presence and absence of its allosteric effectors,
we attempt to discern the dynamics in allosteric regulation of hL-PYK.
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4.1.1

Structural Analysis of hL-PYK

Figure 4.1 Structure of hL-PYK.
(A) The tetrameric structure of hL-PYK with its two interfaces labelled. (B) Monomer of hLPYK with its labeled four domains. The active site is in yellow space fill, the Alanine allosteric
site is in red space fill, and the Fructose-1,6-bisphosphate (FBP) site is in blue space fill.
Structurally, hL-PYK is a homo-tetramer, where each monomer houses four
distinguishable domains: A, B, C, and N-terminal domains. 88 The A-domain is a TIM-barrel fold
(eight α-helices and eight β-strands) that harbors the active site. Above the catalytic domain,
resides the flexible B-domain; previous studies of PYK have shown that this B-domain encloses
the active site upon substrate binding, acting as a capsid. 91 Below the A-domain resides the Cdomain, comprised of five α-helices and β-strands. The FBP allosteric binding site is housed
here, while the alanine allosteric binding site can be found at the interface of domains A and C.
The N-terminus domain, which is uniquely present in mammalian PYK, is responsible for the
hormonal regulation of hL-PYK.92
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Each monomer interacts with one another through two interfaces – the A and C
interfaces. As aptly named, the A-interface comprise of interactions between the A-domains of
each monomer, while the C-domains interact with one another at the C-interface. Previous
experimental studies on pyruvate kinase isoforms have shown cooperativity, suggesting that
dynamical information can be relayed across monomers through the interfaces. 86 Regarding the
active site, the substrate PEP binds in coordination with a divalent magnesium cation, and a
monovalent potassium ion. Not only are these ions necessary for enzymatic activity, but an
ADP·Mg2+ complex within the active site is also required.
In previous studies, allosteric regulation of hL-PYK with FBP was explored through a
variety of mutations.93,94 Based on the mutations done near the FBP binding site, Ishwar et.al.
hypothesized that in the absence of FBP, the effector loop (residues 527-533) would interact with
residue D499 across the C-interface, and that the affinity towards PEP would be lowered in
accordance to this conformation.93 They observed that mutations D499N and W527H led to an
increase in PEP affinity without FBP treatment, and further hypothesized that activation of hLPYK was caused by disrupting the hypothesized interactions between D499 and W527 and/or
R528.
In this study, we run MD simulations of hL-PYK both in the presence and absence of
FBP. Our findings show that in the absence of FBP, residues D499 indeed interacts with W527
and R528 across the C-interface, supporting the previous hypothesis proposed by Ishwar et al. 93
Our findings also show that FBP binding to hL-PYK disrupts a multitude of interactions across
the C-interface. In addition, we run an MD simulation of hL-PYK-alanine complex. Our results
show that upon binding of alanine, the dynamics of hL-PYK shift to a more “open” conformation
that correlates to motions observed in previous studies on PYK homologues.
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4.2

Experimental Procedures
4.2.1

Preparation of hL-PYK for MD Simulations

All crystal structures of hL-PYK have disordered and partly unresolved B-domains, while
the rest of the protein is well resolved (and interpretable). This would suggest that the B-domain
is capable of adopting multiple conformations even when crystallized. Before MD simulations of
hL-PYK could be performed, it was important to first model these highly dynamic missing
residues. We used PDB 4IP7, hL-PYK in complex with citrate and FBP, as the starting model. 95
Using PyMOL78, the coordinates of the missing atoms in the B-domain were acquired through
superposition of the PYK monomers from PDB’s 4IP7, 4IMA, and 2VGB. The first 25 residues
of the N-terminus are unresolved in all crystal structures of hL-PYK due to its large flexibility.
The software Modeller96 was used to approximate the missing N-terminus residues.
In the active site of PDB 4IP7 (the starting model for our MD simulations), citrate is in
place of PEP, and Manganese is in place of Magnesium. There is no ADP in the crystallized
structure. The coordinates of chain A from PDB 4HYV97, which contains PEP in the conserved
active site, was superimposed to each chain of PDB 4IP7. The coordinates of the PEP were then
transferred onto the hL-PYK model. The coordinates of ADP-Mg 2+ were acquired from
superimposing chain A of PDB 3GR4 onto each monomer of hL-PYK. The fidelity of these
clippings was confirmed through xLeap. Previous studies have found the alanine (allosteric
inhibitor) binding site to be conserved between rabbit muscle pyruvate kinase and hL-PYK. To
generate an alanine-bound hL-PYK model, PDB 2G5098 (from the rabbit muscle isozyme) was
superimposed onto each monomer of the hL-PYK system, where the coordinates of alanine were
then transferred onto the allosteric site of hL-PYK.
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4.2.2

MD Simulations of hL-PYK

The molecular dynamics simulations were carried out using the CUDA version of the
Amber16 suite of programs79 along with the modified version of the Cornell et al. ff14SB 80 force
field. Each simulation ran using the NVIDIA GeForce GTX 980 GPU. The x-ray crystal
structure PDB 4IP7 (resolution of 1.8 Å) was used as the initial structure of hL-PYK. The
GAFF279 Force Field was used to parameterize the ligands. The forcefield for ADP was acquired
from the Bryce group (AMBER parameter database from Manchester). 99
Each system was solvated in a TIP3P35 periodic octahedron box containing water
molecules. Counterions were added to the system to obtain electrostatic neutrality. All
simulations were kept at a Temperature of 300 K and a constant pressure of 1 bar. Electrostatic
interactions were calculated using the particle mesh Ewald (PME) summation method, where
long-range nonbonded interactions were accounted for with a 9 Å cutoff. 82 For each system a 2
fs time step was used to solve the equation of motion. After a series of minimizations, the system
was equilibrated with a harmonic constraint through five subsequent MD simulations of 1 ns
each, where the force constant was reduced from 500 to 5 kcal·Å2/mole. A final equilibration
step was performed for 1 ns, where no harmonic constraints were conducted; this allowed the
enzyme complex to move freely. All images of the structures were generated through VMD 83.

Table 4.1 Summary of MD simulations performed on hL-PYK.
MD Simulations

Ligands

Timescale

1

hL-PYK

4 PEP, 4 ADP, 8 Mg2+, 4 K+

1.1 µs

2

hL-PYK · FBP

4 PEP, 4 ADP, 8 Mg2+, 4 K+, 4 FBP

1.1 µs

3

hL-PYK · Alanine

4 PEP, 4 ADP, 8 Mg2+, 4 K+, 4 Alanine

1.1 µs
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4.3

Results & Discussion

Figure 4.2 RMSD of the hL-PYK monomers.
Each graph represents a separate monomer, with the chain labelled at the bottom left.
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Figure 4.3 RMSD of hL-PYK bound to FBP.
Each graph represents a separate monomer, with the chain labelled at the bottom left.
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Figure 4.4 RMSD of hL-PYK bound to Alanine.
Each graph represents a separate monomer, with the chain labelled at the bottom left.
As mentioned previously, RMSD is useful in determining convergence of a molecular
system. An important consideration here is that the RMSD method relies on rigid-body
alignment of an ensemble of structures, and this method of alignment is incredibly sensitive to
flexible regions of a molecular body. Therefore, superimposing an entire macromolecule
(including the flexible subsets of the molecule) can often lead to unnecessarily large RMSD
values. Given that previous crystallographic studies have found both the N and B-domains of
PYK to fluctuate greatly, we masked out the first twenty-five residues of the N-terminus domain
for all calculations. For the sake of RMSD calculations, the B-domain was also masked out, but
all other analysis is done with the inclusion of this flexible domain.

44

Based on the RMSD, it appears that most chains reach convergence over the
microsecond-long simulation, but some notable issues should be considered. Chain D of the
standard hL-PYK trajectory (absence of allosteric effector) appears to continuously rise in its
RMSD over time, indicating that it may not be fully stabilized. This same characteristic is absent
in the other two hL-PYK simulations, where chain D appears to stabilize fairly quickly in the
presence of allosteric effectors. Given the difficulty in crystallizing the tetramer, it is plausible to
suggest that the starting coordinates of the monomers could sample different conformations.

Figure 4.5 RMSF of the hL-PYK simulations.
(A) RMSF of hL-PYK. (B) RMSF of hL-PYK in complex with FBP. (C) RMSF of hL-PYK in
complex with alanine. Given that hL-PYK is a homo-tetramer, the panels are ordered from
chains A to D.
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Figure 4.6 Comparison of RMSF of hL-PYK.
(A) Difference in RMSF between hL-PYK and hL-PYK-FBP. (B) Difference in RMSF between
hL-PYK and hL-PYK-Alanine. Given that hL-PYK is a homo-tetramer, the panels are ordered
from Chains A to D.
Results from the RMSF calculations of the systems show a great deal of dynamical
differences occurring in the B-domains (residues 143-230) of each monomer. It appears that
upon binding of either FBP or alanine, the B-domains fluctuate greatly. In addition, the FBP
effector loops (residues 527-533) undergo large fluctuations in both the FBP bound simulation,
and even the alanine-bound hL-PYK system. This could suggest that the dynamics induced by
alanine inhibition are linked to the FBP binding site.
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Figure 4.7 PC plots of the PYK monomers.
Top graphs display PC1 vs. PC2 of the monomers. Black is representative of hL-PYK, red
represent Alanine bound hL-PYK, and blue represent FBP bound hL-PYK. Bottom plots are PC1
and PC2 with respect to time.

Figure 4.8 Dominant motions revealed by PCA of the monomers.
(A) Conformation of the hL-PYK monomer when PC1 equals 75. (B) Conformation of the hLPYK monomer when PC1 equals -75.
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To capture the most dominant motions at the monomeric level, PCA was performed on
the individual chains of the PYK trajectories. As expected, the B-domain exerts most of the
motions. Chain A and B of all simulations appear to overlap in PC1 and PC2, indicating that the
dominant motions these two chains exert are identical. This could suggest that the dynamics
induced by allostery are subtle, and that other techniques could aid in uncovering them.
Interestingly, chains C and D of the hL-PYK-alanine simulations exert a different motion after
500 nanoseconds. Here, the B-domain appears to open up, exposing the active site as a result.
Previous studies on PYK isozymes have proposed that an inactive PYK would orient itself so
that the B-domains would rotate outwards (away from the catalytic site). 100 PC1 of the hL-PYK
systems demonstrates that both chains C and D undergo this “opening” movement when bound
to alanine.
There are multiple explanations as to why chains A and B of the alanine-PYK complex
sample a more closed/rigid conformation in regard to the B-domain. For one, this could be a case
where hL-PYK could function as a dimer of dimers, which has been proposed in previous
studies. Less optimistically, it is possible that these allosteric transitions require longer timescale
simulations. This could suggest that the conformation transition of all monomers is not
simultaneous. That being said, the chains C and D conformation shift piqued enough interest for
further exploration; in a later section, we compare the dynamics from this particular
conformation against the standard hL-PYK dynamics.
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Figure 4.9 Dynamical contacts statistics of the hL-PYK tetramer.
(A) Changes of the residue-residue contacts between hL-PYK and hL-PYK-FBP complex. (B)
Changes of the residue-residue contacts between hL-PYK and hL-PYK-alanine. Blue bars
indicate more contact formations, and red bars indicate more contact breakages.
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Figure 4.10 Difference contact network analysis of the hL-PYK simulations.
(A) Communities generated from calculating the residue-residue contact statistics of all hL-PYK
simulations and generating a consensus network (B) dCNA of hL-PYK vs. hL-PYK-FBP
complex. (C) dCNA of hL-PYK vs hL-PYK-alanine complex.
Results from calculating and comparing the contact dynamics of all three simulations
reveals that the dynamics between hL-PYK both in the presence and absence of FBP differ
greatly. At the C-interface, it is apparent that a large number of contacts are broken, revealing
that upon FBP binding, the C-domains from each monomer can shift further away with respect to
each other, breaking contacts as a result. When comparing the dynamics of hL-PYK both in the
presence and absence of alanine, the C-interface has some lesser contact breakages, but in many
cases, more contacts are forming between communities from the C-interface.
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4.3.1

The Role of the FBP Binding Site in hL-PYK Regulation

In previous studies on M1 and M2 PYK crystal structures, interactions between D499 and
W527, and D499 and R528, were found to occur across the C-interface of the tetramer in the
absence of FBP. Residues W527 and R528 reside in the FBP binding site, and crystal structures
of M1 and M2 PYK show that upon FBP binding, the backbone atoms of these residues interact
with the allosteric effector, leading to a disruption of the previous aforementioned C-interface
contacts.
Recent studies on hL-PYK found that by mutating residues D499, W527, and R528, the
enzyme would exhibit an increase in substrate affinity without need of the FBP effector,
suggesting that the perturbation of these residue-residue contacts could lead to an increase in
substrate affinity. Due to the lack of reliable crystal structures of hL-PYK, these contacts are
merely a speculation. A very recent crystallographic study on hL-PYK attempted to explore this
hypothesis by solving the structures of these PYK mutations, but complications arose from
resolving the crystal structures, and the C-interface contacts in the absence of FBP were not
observed.

Figure 4.11 Comparison of the FBP effector loop in MD sampled hL-PYK.
(A) The hL-PYK-FBP complex. FBP interacts with the backbone of loop 527-533. (B) hL-PYK
in the absence of FBP. The W527 and R528 sidechains from one monomer interact with D499
from another monomer, forming interactions across the C-interface. These interactions have only
been hypothesized in hL-PYK.
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Figure 4.12 Probability distribution of the distances between FBP effector loop and D499
(A) Distance measured from CZ of R528 and CD of D499. (B) Distance measured from NZ of
W527 and CD of D499. Black represents hL-PYK, blue represents the hL-PYK-FBP complex,
and red represents the hL-PYK-alanine complex.
Results from our MD simulations show that when hL-PYK is simulated without FBP, the
allosteric effector loop moves across the C-interface, where residues R528 and W527 from one
chain, interacts with D499 from another. When FBP is in complex with hL-PYK, this effector
loop is pulled away from the C-interface, and the distance between the side-chains are 10-20 Å.
Based on the observed motions in our MD simulations, as well as the previous mutational studies
done on residues D499 and W527, we propose that FBP allosterically activates hL-PYK by
disrupting C-interface interactions between W527-D499 and R528-D499. Furthermore,
difference contact statistics showcase that many residue-residue interactions across the Cinterface are disrupted upon FBP binding, insinuating that the shifts of the C-domains away from
one another are correlated to PYK activation. We hypothesize that mutations on D499, W527,
and R528 would not only lead to an increase in hL-PYK activity, but that the dynamics would
also resemble that of FBP bound hL-PYK.
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4.3.2

Speculation on the Monomeric Dynamics Induced via Alanine Binding

Figure 4.13 Dynamical contact statistics of the last 500 ns of chains C & D.
Changes of the residue-residue contacts between hL-PYK and hL-PYK-alanine at the
monomeric level. The last 500 nanoseconds of Chains C and D were used since they exhibited
B-domain “opening” motions. The active site is in yellow space-fill, and the alanine binding site
is in pink space-fill. Blue bars indicate more contact formations, and red bars indicate more
contact breakages.

Figure 4.14 Difference contact network analysis of hL-PYK vs alanine-bound hL-PYK.
(A) Communities generated from calculating the residue-residue contact statistics and generating
a consensus network. (B) Difference contact network analysis (dCNA) reveals community-level
dynamical changes.
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Previous studies on PYK isozymes have attributed the enzyme’s allosteric inactivation to
the “opening” of its B-domain.100 In an attempt to discern the dynamical changes induced by
alanine inhibition of hL-PYK, we ran and analyzed an MD simulation of hL-PYK-alanine
complex. PCA revealed that chains C and D began to sample a B-domain opening shift around
500 nanoseconds, while chains A and B managed to remain intact for the entire 1.1 microsecond
trajectory. We therefore speculate that these last 500 ns of chains C and D could provide insight
on the role alanine plays in the conformational dynamics of hL-PYK, at least at the monomeric
level.
Difference contact statistics between hL-PYK and hL-PYK-alanine reveals significant
motions of both the A and B domains. In the hL-PYK-alanine complex, the B-domain tilts
outward, exposing the catalytic site by forming contacts on one corner (through a tilt) and
breaking contacts with the A-domain on the other corner. This entire domain shift reinforces the
notion that the B-domain acts as a capsid, where upon binding of the inhibitor alanine, the
domain “opens” up and exposes the active site. In addition, residues in the catalytic A-domain
(TIM barrel fold) form more contacts with one another in the alanine bound simulation, which
could suggest that allosteric inhibition by alanine leads to contraction of the TIM barrel domain.
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4.4

Conclusions
Previous structural studies on hL-PYK have had difficulty in coming up with models that

would explain the structural conformation shifts induced by allostery. In an attempt to uncover
an atomic-level mechanism involved in hL-PYK allosteric regulation, we set out on our
exploration using MD simulations of the enzyme both in the presence and absence of the
allosteric effectors.
Results from our MD simulations show that in the absence of FBP, a great deal of contacts
form across the C-interface, and that the FBP effector loop (527 to 533) from one monomer
interacts with D499 from another. Furthermore, we found that FBP binding induces a great deal
of contact breakages across the C-interface, with the interactions between W527-D499 and
R528-D499 being perturbed greatly. Interestingly, we found that in the MD simulation of alanine
bound hL-PYK, these residues interact with one another even more-so, suggesting a possible
synergy between the two allosteric effectors. These findings support the hypothesis that residues
W527, R528, and D499 are key to allosteric regulation of hL-PYK.
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5

CONCLUSIONS

In this study, we explored the dynamics of two enzymes involved in glycolysis in the
context of regulation. Despite being metabolically coupled, the two enzymes have distinct
regulatory features that make them worth exploring individually.
In the enolase study, we found that the free-state dynamics of the two isozymes, enolase 1
and 2, are very different despite their high conservation. MD simulations of the two enzymes
bound to compound HEX, an enolase 2 selective inhibitor, found that the ligand induces greater
dynamical changes to enolase 2 than enolase 1. As a point of interest, we embarked on ensemble
virtual screening to further distinguish the dynamics of free enolase 1 and 2. Our results led to
the discovery of compounds that could be potentially selective to enolase 1, while not a single
compound could bind significantly more favorably to enolase 2. This not only reinforces that the
dynamics of these two highly conserved homologues are different, but the results could suggest
that enolase 1 is more promiscuous.
Given the past difficulties in interpreting the structural motions involved in allosteric
regulation of hL-PYK, we embarked on a mission to uncover an atomic-level detailed model of
hL-PYK allostery. The results from our MD simulations show that in the absence of allosteric
effectors, hL-PYK forms a great deal of contacts across the C-interface, with contacts between
W527 and D499 being the most notable ones. Upon binding of FBP, a great deal of contacts
across the C-interface, particularly the interaction between W527 and D499, are disrupted. Based
on the results of previous mutational studies conducted on the FBP binding site, we propose that
FBP activates the enzyme by disrupting contacts across the C-interface, and these contact
disruptions are facilitated by the stabilization of the FBP effector loop (residues 527-533). As an
extension, we propose that mutating residues D499 or W527 could induce dynamical changes to
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hL-PYK that resemble that of FBP. MD simulations of hL-PYK in complex with alanine show
that some of the monomers can undergo entire domain motions at the nanosecond timescale.
Chains C and D of the trajectory had the entire B-domain shift outwards, exposing the active site
as a result. This conformation has been observed in some previous studies on PYK isozymes.
Because chain A and B remained in a fixed/overlap conformation throughout the 1.1
microsecond simulation, we conclude that the conformational dynamics induced by alanine are
not simultaneous across the monomers. Ultimately, our findings provide some insight on the role
dynamics play in glycolysis regulation.
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